Thromb Haemost 1996; 76(01): 005-008
DOI: 10.1055/s-0038-1650512
Rapid Communication
Schattauer GmbH Stuttgart

Antithrombin-mediated Inhibition of Factor Vlla-Tissue Factor Complex by the Synthetic Pentasaccharide Representing the Heparin Binding Site to Antithrombin

Jean Claude Lormeau
The Haemobiology Research Department, Sanofi Recherche, Toulouse, France
,
Jean Pascal Herault
The Haemobiology Research Department, Sanofi Recherche, Toulouse, France
,
Jean Marc Herbert
The Haemobiology Research Department, Sanofi Recherche, Toulouse, France
› Author Affiliations
Further Information

Publication History

Received: 23 November 1995

Accepted after resubmission01 April 1996

Publication Date:
26 July 2018 (online)

Summary

We examined the effect of the synthetic pentasaccharide representing the minimal binding site of heparin to antithrombin on the antithrombin-mediated inactivation of factor Vila bound to tissue factor. This effect was compared to the effect of unfractionated heparin. Using purified recombinant human coagulation factors and either a clotting or an amidolytic assay for the determination of the residual activity of factor Vila, we showed that the pentasaccharide was an efficient antithrombin-dependent inhibitor of the coagulant activity of tissue factor-factor Vila complex. In our experimental conditions, assuming a mean MW of 14,000 for heparin, the molar pseudo-first order rate constants for ATIII-mediated FVIIa inhibition by ATIII-binding heparin and by the synthetic pentasaccharide were found to be similar with respective values of 104,000 ± 10,500 min-1 and 112,000 ± 12,000 min-1 (mean ± s.e.m., n = 3)

 
  • References

  • 1 Rao LVM, Rapaport SI. Activation of factor VII bound to tissue factor: A key early step in the tissue factor pathway of blood coagulation. Proc Natl Acad Sci USA 1988; 85: 6686-6691
  • 2 Nemerson Y. Tissue factor and haemostasis. Blood 1988; 71: 1-8
  • 3 Rapaport SI, Rao LVM. Initiation and regulation of tissue factor-dependent blood coagulation. Arteriosclerosis and Thrombosis 1992; 12: 1111-1121
  • 4 Broze Jr GJ, Girard TJ, Novotny WF. Regulation of coagulation by a multivalent Kunitz-type inhibitor. Biochem 1990; 29: 7539-7546
  • 5 Rapaport SI. The extrinsic pathway inhibitor: A regulator of tissue factor-dependent blood coagulation. Thromb Haemost 1991; 66: 6-15
  • 6 Godal HC, Rygh M, Laake K. Progressive inactivation of purified factor Vila by heparin and antithrombin III. Thromb Res 1974; 5: 773-775
  • 7 Kondo S, Kisiel W. Regulation of factor Vila activity in plasma: Evidence that antithrombin III is the sole plasma protease inhibitor of factor Vila. Thromb Res 1987; 46: 325-335
  • 8 Jesty J. The inhibition of activated bovine coagulation factors X and VII by antithrombin III. Arch Biochem Biophys 1978; 185: 165-173
  • 9 Osterud B, Miller-Andersson M, Abildgaard U, Prydz H. The effect of antithrombin III on the activity of the coagulation factors VII, IX and X. Thromb Haemost 1976; 35: 295-304
  • 10 Rao LMV, Rapaport SI, Hoang AD. Binding of factor Vila to tissue factor permits rapid antithrombin Ill/heparin inhibition of factor Vila. Blood 1993; 81: 2600-2607
  • 11 Rao LMV, Nordfang O, Hoang AD, Pendurthi UR. Mechanism of antithrombin III inhibition of factor Vila/tissue factor activity on cell surfaces. Comparison with tissue Factor Pathway Inhibitor/factor Xa-induced inhibition of factor Vila/tissue factor activity. Blood 1995; 85: 121-129
  • 12 Lawson JH, Butenas S, Ribarik N, Mann KG. Complex-dependent inhibition of factor Vila by antithrombin III and heparin. J Biol Chem 1993; 268: 767-770
  • 13 Broze Jr GJ, Likert K, Higuchi D. Inhibition of factor Vila/tissue factor by antithrombin III and tissue factor pathway inhibitor. Blood 1993; 82: 1679-1690
  • 14 Choay J, Petitou M, Lormeau JC, Sinay P, Casu BJ, Gatti G. Structure-activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity. Biochem Biophys Res Commun 1993; 116: 492-499
  • 15 Lormeau JC, Herault JP. Comparative inhibition of extrinsic and intrinsic thrombin generation by standard heparin, a low-molecular weight heparin and the synthetic ATIII-binding pentasaccharide. Thromb Haemost 1993; 69: 152-156
  • 16 Hobbelen PMJ, Van Dinther TG, Vogel GM, Van Boeckel CAA, Moelker HCT, Meuleman DG. Pharmacological profile of the chemically synthe-tized antithrombin III binding fragment of heparin (pentasaccharide) in rats. Thromb Haemost 1990; 63: 265-270
  • 17 Amar J, Caranobe C, Sie P, Boneu B. Antithrombotic potencies of heparins in relation to their antifactor Xa and antithrombin activities: an experimental study in two models of thrombosis in the rabbit. Br J Haematol 1990; 76: 94-100
  • 18 Scully MF. Kinetic considerations on the physiologic control of thrombin and factor Xa. Sem Thromb Haemost 1992; 18: 218-223
  • 19 Lormeau JC, Herault JP. The effect of the synthetic pentasaccharide SR 90107/ORG 31540 on thrombin generation ex vivo is uniquely due to ATIII-mediated neutralization of factor Xa. Thromb Haemost 1995; 74: 1474-1477
  • 20 Nordenman B, Danielsson A, Bjork I. The binding of low affinity and high affinity heparin to antithrombin. Fluorescence studies. Eur J Biochem 1978; 90: 1-6
  • 21 Crepon B, Donat F, Barzu T, Herault JP. Pharmacokinetic parameters of ATIII-binding pentasaccharides in three animal species: Predictive value for humans. Thromb Haemost 1993; 69: 403
  • 22 Boneu B, Necciari J, Magnani H, Kieffer G, Mant T, Morrison P, Singer B, Lamond G, Dickinson J. Pharmacokinetics of the natural pentasaccharide (SR 90107A/ORG 31540) with high affinity for antithrombin III following subcutaneous administration in man. Thromb Haemost 1993; 69: 406 (Abstr)
  • 23 Olson TS, Bjork I, Sheffer R, Craig PA, Shore JD, Choay J. Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrom-bin-proteinase reactions. J Biol Chem 1992; 267: 12528-12538